Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)

Ziyang Cao; Yi Shu; Jinxia Wang; Chunxia Wang; Tienan Feng; Li Yang; Jingbo Shao; Lin Zou

doi:10.1016/j.gendis.2022.01.006

您当前的位置：

首页 >

文章列表页 >

Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)

Review article | 更新时间：2022-11-09

- Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)
- Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)
- Genes & Diseases 2022年9卷第6期
- 作者机构：
  
  1. Clinical Research Unit, Shanghai Children's Hospital, Shanghai Jiao Tong University,Shanghai,PR China,200062
  2. Institute of Pediatric Infection, Immunity, Critical Care Medicine, Shanghai Jiao Tong University School of Medicine,Shanghai,PR China,200062
  3. Center for Clinical Molecular Laboratory Medicine of Children's Hospital of Chongqing Medical University,Chongqing,PR China,400014
  4. Clinical Research Institute, Shanghai Jiao Tong University School of Medicine,Shanghai,PR China,200025
  5. Department of Hematology, The First Affiliated Hospital of Chongqing Medical University,Chongqing,PR China,400016
  6. Department of Hematology/Oncology, Shanghai Children's Hospital, Shanghai Jiao Tong University,Shanghai,PR China,200062
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.01.006
  中图分类号：
- 纸质出版日期：2022，
  
  网络出版日期：2022-11-1，
扫描看全文
Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)[J]. Genes & Diseases, 2022,9(6).

Ziyang Cao, Yi Shu, Jinxia Wang, et al. Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)[J]. Genes & Diseases, 2022,9(6).
Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)[J]. Genes & Diseases, 2022,9(6). DOI： 10.1016/j.gendis.2022.01.006.

Ziyang Cao, Yi Shu, Jinxia Wang, et al. Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)[J]. Genes & Diseases, 2022,9(6). DOI： 10.1016/j.gendis.2022.01.006.

摘要

Abstract

ute myeloid leukemia (AML) is a malignant hematological tumor with disordered oncogenes/tumor suppressor genes and limited treatments. The potent anti-cancer effects of bromodomain and extra-terminal domain (BET) inhibitors

targeting the key component of super enhancers

in early clinical trials on AML patients

implies the critical role of super enhancers in AML. Here

we review the concept and characteristic of super enhancer

and then summarize the current researches about super enhancers in AML pathogenesis

diagnosis and classification

followed by illustrate the potential super enhancer-related targets and drugs

and propose the future directions of super enhancers in AML. This information provides integrated insight into the roles of super enhancers in this disease.

关键词

Keywords

AMLClassificationLeukemogenesisSuper enhancerTherapy targets

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

RNA m⁶A reader YTHDF2 facilitates precursor miR-126 maturation to promote acute myeloid leukemia progression

Overcoming adaptive resistance in AML by synergistically targeting FOXO3A-GNG7-mTOR axis with FOXO3A inhibitor Gardenoside and rapamycin